Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of anti-CD19 antibody and anti-CD5 antibody

An antibody and monoclonal antibody technology, applied in the new application field of anti-CD19 antibody and anti-CD5 antibody, can solve problems such as unanimous affirmation

Inactive Publication Date: 2013-04-10
PEOPLES HOSPITAL PEKING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treatments such as hyperbaric oxygen, intravesical injection of rhGM-CSF or hyaluronic acid and even cystectomy have been reported to be effective, but they have not been unanimously confirmed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anti-CD19 antibody and anti-CD5 antibody
  • Application of anti-CD19 antibody and anti-CD5 antibody
  • Application of anti-CD19 antibody and anti-CD5 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0027] Of the 25 confirmed LOHC patients, 24 were treated according to the scheduled procedures.

[0028] Since only 9 of all patients were positive for CMV in the initial etiological test, and the rest were negative, only CMV was detected in subsequent etiological tests.

[0029] 1. Antiviral treatment

[0030] Twenty-four patients received antiviral therapy (17 cases were given sodium foscarnet; 7 cases were given ganciclovir). Etiological tests were performed twice in the first week: patients who were negative twice received antiviral treatment for 10-14 days (blood CMV pathogenic tests were performed twice a week), and then the efficacy was evaluated; patients with positive results continued to receive antiviral treatment. Virus treatment (etiology detection twice a week), until the results are negative for two consecutive times, the curative effect will be evaluated.

[0031] Among the 24 patients, antiviral treatment was effective in 6 patients, and antiviral treatment...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application of an anti-CD19 antibody and an anti-CD5 antibody. The anti-CD19 antibody and the anti-CD5 antibody are applied to preparing a reagent for detecting the curative effect of glucocorticoid and antiviral medicaments on tardive hemorrhagic cystitis. In the invention, a tardive hemorrhagic cystitis patient ineffectively treated by hydration, alkalization and antivirus is treated by utilizing the glucocorticoid and the antivirus, the curative effect is observed and the variation of peripheral blood B lymphocyte subpopulations at different stages when the patient suffers from a disease is monitored. A majority of patients are found to have response on hormone treatment, and the curative effect is obviously related to the ratio of CD19+CD5+B cell subpopulation. If the ratio of the CD19+CD5+B cell subpopulation accounting for B cells at some stage of the patient is obviously higher than that of the patient when suffering from the disease, the glucocorticoid auxiliary treatment is hinted to achieve better curative effect. The invention has significant meaning on the treatment of the tardive hemorrhagic cystitis patient.

Description

technical field [0001] The present invention relates to new uses of anti-CD19 antibody and anti-CD5 antibody. Background technique [0002] Late-onset hemorrhagic cystitis (LOHC) is a common complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Severe LOHC often leads to prolonged hospital stay and increased suffering. The clinical symptoms of LOHC vary. Mild cases only show microscopic hematuria, while severe cases can cause urinary tract obstruction and even threaten the life of the patient. The mechanism of delayed hemorrhagic cystitis remains unclear. Most reports claim that viral infections, such as BKV, CMV, ADV, etc., especially BK virus are closely related to the occurrence of LOHC. However, the conclusion that viral infection causes LOHC is currently only based on the presence of viremia and / or viruria in LOHC patients, or the presence of virus can be detected in bladder mucosal epithelial cells, and it is still unclear how viral infectio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/74G01N33/577G01N33/569
Inventor 黄晓军阮国瑞刘开彦刘代红许兰平付海霞
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com